{"protocolSection":{"identificationModule":{"nctId":"NCT00530621","orgStudyIdInfo":{"id":"9820"},"secondaryIdInfos":[{"id":"H6Q-MC-JCBT","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer","officialTitle":"A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl Versus Placebo Concurrently With Pemetrexed (Alimta®) as Second-Line Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2020-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-09"},"primaryCompletionDateStruct":{"date":"2008-10","type":"ACTUAL"},"completionDateStruct":{"date":"2008-10","type":"ACTUAL"},"studyFirstSubmitDate":"2007-09-13","studyFirstSubmitQcDate":"2007-09-13","studyFirstPostDateStruct":{"date":"2007-09-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-06-09","resultsFirstSubmitQcDate":"2020-06-09","resultsFirstPostDateStruct":{"date":"2020-07-01","type":"ACTUAL"},"dispFirstSubmitDate":"2009-10-16","dispFirstSubmitQcDate":"2009-10-16","dispFirstPostDateStruct":{"date":"2009-10-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-06-09","lastUpdatePostDateStruct":{"date":"2020-07-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":160,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Enzastaurin","type":"EXPERIMENTAL","interventionNames":["Drug: enzastaurin","Drug: pemetrexed"]},{"label":"Pemetrexed + Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo","Drug: pemetrexed"]}],"interventions":[{"type":"DRUG","name":"enzastaurin","description":"1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression","armGroupLabels":["Pemetrexed + Enzastaurin"],"otherNames":["LY317615"]},{"type":"DRUG","name":"placebo","description":"oral, daily","armGroupLabels":["Pemetrexed + Placebo"]},{"type":"DRUG","name":"pemetrexed","description":"500 milligrams per square meter (mg/m\\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression","armGroupLabels":["Pemetrexed + Enzastaurin","Pemetrexed + Placebo"],"otherNames":["LY231514","Alimta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from date of randomization to the first documented observation of disease progression or death from any cause. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. PFS was censored at the date of the last objective progression-free disease assessment for participants who did not experience PD or death at the data inclusion cut-off date.","timeFrame":"Baseline to measured progressive disease up to 9.92 months"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date the participant was last known to be alive.","timeFrame":"Baseline to date of death from any cause up to 12.32 months"},{"measure":"Time-to-Worsening (TW) in Lung Cancer Symptom Scale (LCSS) - Health Related Quality of Life (HRQoL) Subscale","description":"LCSS is a participant rated lung cancer instrument which consisted of 6 disease related symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 quality of life (QoL) items (activity status, symptomatic distress, and overall QoL). TW in LCSS-HRQoL was measured from the date of enrollment to the first date of a 15 millimeters (mm) worsening in the 9th LCSS item on QoL. LCSS-HRQoL was measured on the 100-mm visual analogue scale (VAS) with the scores ranging from 0 (best response and very high HRQoL) to 100-mm (worse response and very low HRQoL). TW-HRQoL was censored at the date of the participant's last LCSS assessment for participant without a 15-mm increase on the 100-mm VAS.","timeFrame":"Baseline to disease worsening up to 10.58 months"},{"measure":"Duration of Disease Control (DDC)","description":"DDC was defined as the time from randomization to the first documented observation of disease progression or death from any cause and was limited to the participants with a best tumor response of complete response (CR), partial response (PR), or stable disease (SD). Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. SD was defined as small changes that did not meet the above criteria. DDC was censored at the date of the last objective progression-free disease assessment for participants who did not experience PD or death.","timeFrame":"Baseline to measured progressive disease up to 9.92 months"},{"measure":"Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate)","description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Participants with a best response of complete response (CR) or partial response (PR) were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants was calculated as the total number of participants affected divided by the number of participants analyzed then multiplied by 100.","timeFrame":"Baseline to measured progressive disease up to 9.92 months"},{"measure":"Tumor Biomarkers","description":"Protein expression was measured using an Immunohistochemistry (IHC) assay from the tumor tissue samples. IHC histo-scores (H-scores) were determined separately for each of the 3 biomarkers: folate receptor alpha (FR alpha) in cytoplasm and apical membrane, thymidylate synthase (TS) in cytoplasm and nucleus, and thyroid transcription factor-1 (TTF1) in the nucleus. Tumor tissue samples were to be scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic and nuclear staining. IHC H-score was calculated using the formula: 1 \\* (percentage of cells stained 1+) + 2 \\* (percentage of cells stained 2+) + 3 \\* (percentage of cells stained 3+), giving a minimum score of 0 to a maximum score of 300. The maximum score indicates the strongest expression.","timeFrame":"Tumor samples collected at baseline"}],"otherOutcomes":[{"measure":"Number of Participants Who Died During the Study Treatment","description":"Reported are the deaths due to study disease and adverse events (AEs) that occurred while on study treatment.","timeFrame":"Baseline through study completion [up to 16 Cycles (21-day cycles, except Cycle 1 [28 days])]"},{"measure":"Number of Participants Who Died During the 30 Days After Treatment Discontinuation","description":"Reported are the deaths due to study disease and adverse events (AEs) that occurred during the 30 days after treatment discontinuation.","timeFrame":"End of study treatment [16 Cycles (21-day cycles, except Cycle 1 [28 days])] through 30 days after treatment discontinuation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Laboratory confirmed diagnosis of NSCLC with locally advanced or metastatic disease which cannot be cured.\n* Participants must have disease which progressed after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease.\n* At least 1 measurable lesion.\n* Must have stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment.\n* Must be able to follow study guidelines and be able to show up for appointments.\n\nExclusion Criteria:\n\n* Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.\n* Previous treatment with enzastaurin or pemetrexed.\n* Concurrent administration of any other antitumor therapy.\n* Inability to swallow tablets.\n* Pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lancaster","state":"California","zip":"93534","country":"United States","geoPoint":{"lat":34.69804,"lon":-118.13674}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Scarborough","state":"Maine","zip":"04074","country":"United States","geoPoint":{"lat":43.57814,"lon":-70.32172}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dayton","state":"Ohio","zip":"45429","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Richardson","state":"Texas","zip":"75080","country":"United States","geoPoint":{"lat":32.94818,"lon":-96.72972}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Grenoble","zip":"38043","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Marseille","zip":"13009","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cologne","zip":"D-51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Großhansdorf","zip":"D-22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aviano","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orbassano","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Coimbra","zip":"3040-853","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lisbon","zip":"1099-035","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Presented in the participant flow are the reasons participants discontinued from study treatment.","groups":[{"id":"FG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"FG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"80"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"80"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"80"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Progressive Disease (PD)","reasons":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Subject Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Not Treated Due to PD Prior to Dosing","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"BG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"160"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.2","spread":"9.21"},{"groupId":"BG001","value":"61.6","spread":"9.57"},{"groupId":"BG002","value":"61.4","spread":"9.36"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"52"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"108"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"142"}]}]},{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"38"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"34"}]}]},{"title":"Portugal","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"16"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"40"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"20"}]}]},{"title":"South Korea","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Disease Stage at Study Entry","description":"Disease stage describes how big the tumor is and how far it has spread from the site of origin. Stages ranged from Stage I to Stage IV. Stage III is further separated into Stage IIIA (cancer is locally advanced and spread to nearby lymph node) and Stage IIIB (cancer has spread to distant lymph nodes and invaded other organs like heart or esophagus). Stage IV has cancer spread throughout the body.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Stage IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"39"}]}]},{"title":"Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"115"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from date of randomization to the first documented observation of disease progression or death from any cause. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. PFS was censored at the date of the last objective progression-free disease assessment for participants who did not experience PD or death at the data inclusion cut-off date.","populationDescription":"All randomized participants. Twenty five (25) participants in Pemetrexed + Enzastaurin group and twenty three (23) participants in Pemetrexed + Placebo group were censored for analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to measured progressive disease up to 9.92 months","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.96","lowerLimit":"1.87","upperLimit":"3.58"},{"groupId":"OG001","value":"3.02","lowerLimit":"1.74","upperLimit":"3.98"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.544","pValueComment":"P-value was stratified by Eastern Cooperative Oncology Group (ECOG) performance status and time since last chemotherapy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.13","ciPctValue":"95","ciLowerLimit":"0.77","ciUpperLimit":"1.65"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date the participant was last known to be alive.","populationDescription":"All randomized participants. Fifty three (53) participants in Pemetrexed + Enzastaurin group and forty five (45) participants in Pemetrexed + Placebo group were censored for analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to date of death from any cause up to 12.32 months","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","lowerLimit":"8.18","upperLimit":"NA","comment":"Upper limit of 95% confidence interval was not estimable due to high censoring rate."},{"groupId":"OG001","value":"7.39","lowerLimit":"6.41","upperLimit":"NA","comment":"Upper limit of 95% confidence interval was not estimable due to high censoring rate."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.171","pValueComment":"P-value was stratified by Eastern Cooperative Oncology Group (ECOG) performance status and time since last chemotherapy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.70","ciPctValue":"95","ciLowerLimit":"0.42","ciUpperLimit":"1.17"}]},{"type":"SECONDARY","title":"Time-to-Worsening (TW) in Lung Cancer Symptom Scale (LCSS) - Health Related Quality of Life (HRQoL) Subscale","description":"LCSS is a participant rated lung cancer instrument which consisted of 6 disease related symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 quality of life (QoL) items (activity status, symptomatic distress, and overall QoL). TW in LCSS-HRQoL was measured from the date of enrollment to the first date of a 15 millimeters (mm) worsening in the 9th LCSS item on QoL. LCSS-HRQoL was measured on the 100-mm visual analogue scale (VAS) with the scores ranging from 0 (best response and very high HRQoL) to 100-mm (worse response and very low HRQoL). TW-HRQoL was censored at the date of the participant's last LCSS assessment for participant without a 15-mm increase on the 100-mm VAS.","populationDescription":"Randomized participants who had at least 1 baseline and 1 postbaseline LCSS assessment for HRQoL. Thirty (30) participants in Pemetrexed + Enzastaurin group and forty (40) participants in Pemetrexed + Placebo group were censored for the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to disease worsening up to 10.58 months","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.06","lowerLimit":"2.37","upperLimit":"4.63"},{"groupId":"OG001","value":"8.08","lowerLimit":"3.81","upperLimit":"NA","comment":"Upper limit of 95% confidence interval was not estimable due to high censoring rate."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.010","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"2.11","ciPctValue":"95","ciLowerLimit":"1.19","ciUpperLimit":"3.75"}]},{"type":"SECONDARY","title":"Duration of Disease Control (DDC)","description":"DDC was defined as the time from randomization to the first documented observation of disease progression or death from any cause and was limited to the participants with a best tumor response of complete response (CR), partial response (PR), or stable disease (SD). Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. SD was defined as small changes that did not meet the above criteria. DDC was censored at the date of the last objective progression-free disease assessment for participants who did not experience PD or death.","populationDescription":"Randomized participants who received at least 1 dose of study drug and had a best tumor response of CR, PR, or SD. Fourteen (14) participants in Pemetrexed + Enzastaurin group and seventeen (17) participants in Pemetrexed + Placebo group were censored for analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to measured progressive disease up to 9.92 months","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.32","lowerLimit":"3.58","upperLimit":"7.13"},{"groupId":"OG001","value":"6.31","lowerLimit":"4.40","upperLimit":"6.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.194","pValueComment":"P-value was stratified by Eastern Cooperative Oncology Group (ECOG) performance status score and time since last chemotherapy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.50","ciPctValue":"95","ciLowerLimit":"0.81","ciUpperLimit":"2.77"}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate)","description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Participants with a best response of complete response (CR) or partial response (PR) were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants was calculated as the total number of participants affected divided by the number of participants analyzed then multiplied by 100.","populationDescription":"Randomized participants who received at least 1 dose of study drug and had responses evaluated for CR or PR.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to measured progressive disease up to 9.92 months","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets; three (125-mg) tablets administered orally 3 times a day\\] on Day 1 followed by total dose of 500 mg enzastaurin \\[two (125-mg) tablets administered orally 2 times a day\\] on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin \\[two (125-mg) tablets administered orally 2 times a day\\] on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose (total 9 tablets; three tablets administered orally 3 times a day) on Day 1 followed by four placebo tablets (two tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by four placebo tablets (two tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met.\n\n."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"78"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9"},{"groupId":"OG001","value":"2.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.681","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Tumor Biomarkers","description":"Protein expression was measured using an Immunohistochemistry (IHC) assay from the tumor tissue samples. IHC histo-scores (H-scores) were determined separately for each of the 3 biomarkers: folate receptor alpha (FR alpha) in cytoplasm and apical membrane, thymidylate synthase (TS) in cytoplasm and nucleus, and thyroid transcription factor-1 (TTF1) in the nucleus. Tumor tissue samples were to be scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic and nuclear staining. IHC H-score was calculated using the formula: 1 \\* (percentage of cells stained 1+) + 2 \\* (percentage of cells stained 2+) + 3 \\* (percentage of cells stained 3+), giving a minimum score of 0 to a maximum score of 300. The maximum score indicates the strongest expression.","populationDescription":"Randomized participants who had at least 1 biomarker expression value measured at baseline.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"H-scores","timeFrame":"Tumor samples collected at baseline","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG002","title":"Total (Pemetrexed + Enzastaurin and Pemetrexed + Placebo)","description":"Enzastaurin (1125 mg loading dose of 9 tablets) or placebo (loading dose of 9 tablets) administered on Day 1 followed total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) or four placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin \\[two 125-mg tablets administered orally 2 times a day\\] or four placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"46"}]}],"classes":[{"title":"FR Alpha in Cytoplasm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.96","spread":"65.99"},{"groupId":"OG001","value":"24.50","spread":"51.04"},{"groupId":"OG002","value":"41.98","spread":"61.24"}]}]},{"title":"FR Alpha in Apical Membrane","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.96","spread":"24.70"},{"groupId":"OG001","value":"18.25","spread":"48.62"},{"groupId":"OG002","value":"13.64","spread":"37.03"}]}]},{"title":"TS in Cytoplasm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.38","spread":"25.29"},{"groupId":"OG001","value":"22.30","spread":"34.83"},{"groupId":"OG002","value":"18.96","spread":"29.60"}]}]},{"title":"TS in Nucleus","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":"12.55"},{"groupId":"OG001","value":"8.00","spread":"18.84"},{"groupId":"OG002","value":"6.83","spread":"15.44"}]}]},{"title":"TTF-1 in Nucleus","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.88","spread":"71.18"},{"groupId":"OG001","value":"32.35","spread":"72.58"},{"groupId":"OG002","value":"41.13","spread":"71.41"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Died During the Study Treatment","description":"Reported are the deaths due to study disease and adverse events (AEs) that occurred while on study treatment.","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline through study completion [up to 16 Cycles (21-day cycles, except Cycle 1 [28 days])]","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"}]}],"classes":[{"title":"Study Disease","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"AEs","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Died During the 30 Days After Treatment Discontinuation","description":"Reported are the deaths due to study disease and adverse events (AEs) that occurred during the 30 days after treatment discontinuation.","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"End of study treatment [16 Cycles (21-day cycles, except Cycle 1 [28 days])] through 30 days after treatment discontinuation","groups":[{"id":"OG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met."},{"id":"OG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met.\n\n."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"}]}],"classes":[{"title":"Study Disease","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"}]}]},{"title":"AEs","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Study-specific clinical outcomes due to progressive disease (PD) were not considered to be serious adverse events (SAEs) unless the investigator deemed it related to the use of the study drug.","eventGroups":[{"id":"EG000","title":"Pemetrexed + Enzastaurin","description":"Enzastaurin 1125 milligrams (mg) loading dose \\[total 9 tablets (three 125-mg tablets administered orally 3 times a day)\\] on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 2 to 28, and pemetrexed 500 milligrams per square meter (mg/m\\^2) intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by total dose of 500 mg enzastaurin (two 125-mg tablets administered orally 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met.","seriousNumAffected":33,"seriousNumAtRisk":79,"otherNumAffected":73,"otherNumAtRisk":79},{"id":"EG001","title":"Pemetrexed + Placebo","description":"Placebo loading dose \\[total 9 tablets (3 tablets administered orally 3 times a day)\\] on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 2 to 28, and pemetrexed 500 mg/m\\^2 intravenous injection on Day 8 in Cycle 1 (28-day cycle).\n\nPemetrexed 500 mg/m\\^2 intravenous injection on Day 1 followed by 4 placebo tablets (2 tablets 2 times a day) on Days 1 to 21 in Cycle 2 and subsequent cycles (21-day cycle).\n\nTreatment was continued until evidence of disease progression, unacceptable toxicity, or any other discontinuation criteria were met.","seriousNumAffected":30,"seriousNumAtRisk":80,"otherNumAffected":75,"otherNumAtRisk":80}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Anaemia of malignant disease","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Anal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Gastrointestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":80}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Listeriosis","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":80}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":80}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Abnormal behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Renal pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Bronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Mediastinal disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Panniculitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":23,"numAtRisk":79},{"groupId":"EG001","numEvents":22,"numAffected":15,"numAtRisk":80}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":80}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":79},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":80}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":79},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":80}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":11,"numAtRisk":79},{"groupId":"EG001","numEvents":14,"numAffected":5,"numAtRisk":80}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":79},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":79},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":80}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":80}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":79},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":80}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":19,"numAtRisk":79},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":80}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":17,"numAtRisk":79},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":80}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":80}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":38,"numAtRisk":79},{"groupId":"EG001","numEvents":29,"numAffected":20,"numAtRisk":80}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":19,"numAtRisk":79},{"groupId":"EG001","numEvents":18,"numAffected":14,"numAtRisk":80}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":79},{"groupId":"EG001","numEvents":26,"numAffected":17,"numAtRisk":80}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":79},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":80}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":23,"numAtRisk":79},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":80}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":79},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":79},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":80}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":16,"numAtRisk":79},{"groupId":"EG001","numEvents":18,"numAffected":14,"numAtRisk":80}]},{"term":"Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":79},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":80}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":79},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":80}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":28,"numAtRisk":79},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":80}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":80}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":80}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":79},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":79},{"groupId":"EG001","numEvents":13,"numAffected":8,"numAtRisk":80}]},{"term":"Chromaturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":79},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":79},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":80}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":79},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":80}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":79},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":79},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":80}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":79},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":80}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C504878","term":"enzastaurin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}